Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2254)	5/14/2010 2:24:58 PM
From: Jibacoa	Respond to of 3722

OSIP is trying to go above the resistance at the $60 level.<g> The stock is still up 3.34% in spite of the general market, and volume of > 2.7M is above its ADV bigcharts.marketwatch.com Apparently some people are expecting an increase in the offer price of $3.5B for a takeover from Astellas Pharmala.<g> There is no information on wether there could be other possible suitors involved or if Astellas would raise its offer. Astellas' tender offer for OSI expires on May 17. In March in exchange of looking at OSIP's record it agreed that it would not acquire any shares of OSIP until until today.<g> On Apr17 OSIP received approval from the FDA for Terciva to treat advanced NSCL lung Cas. Many people think that the value of OSIP is larger than the $52 price offer from Astellas. However, if Astellas fails to commit to a higher offer and walks away, and there are no other suitors interested, OSIP shares could close some of its March UG.<g> bigcharts.marketwatch.com The May and June $45 puts are lower and the $50 calls are higher today.<g> Bernard